NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis → This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad) Free CRVS Stock Alerts $2.08 +0.05 (+2.46%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$1.91▼$2.1750-Day Range$1.36▼$2.2852-Week Range$1.05▼$4.19Volume307,162 shsAverage Volume284,252 shsMarket Capitalization$102.00 millionP/E RatioN/ADividend YieldN/APrice Target$6.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Corvus Pharmaceuticals alerts: Email Address Corvus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside230.5% Upside$6.88 Price TargetShort InterestHealthy3.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 16 Articles This WeekInsider TradingAcquiring Shares$1.03 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.47) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.91 out of 5 starsMedical Sector383rd out of 921 stocksPharmaceutical Preparations Industry168th out of 428 stocks 3.3 Analyst's Opinion Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCorvus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Corvus Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.69% of the float of Corvus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently decreased by 0.73%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVS. Previous Next 3.3 News and Social Media Coverage News SentimentCorvus Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Corvus Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 17 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat Follows3 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,033,907.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corvus Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($0.47) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corvus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressBuy Friday. Sell Monday. A 35 year old man from central Florida has stumbled on one of the best strategies we’ve seen in a long time. For the last 30 months his “Friday to Monday” trading strategy has maintained a 71% win rate on more than 350 trades. That includes multiple big time winners like 82% from Adobe… 77% from Palo Alto… But also a barrage of smaller winners like 20% from AMC… Each of which were opened on a Friday afternoon and closed the very next Monday morning. As you’ll see in his brand new video, this strange strategy has given him the ability to capture big time market moves over the weekend.Check it out, simply follow this link here. About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Read More CRVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRVS Stock News HeadlinesMay 8, 2024 | insidertrades.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Purchases $34,600.00 in StockMay 10, 2024 | finance.yahoo.comInsider Spends US$1m Buying More Shares In Corvus PharmaceuticalsMay 11, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 8, 2024 | americanbankingnews.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) CEO Richard A. Md Miller Purchases 577,634 Shares of StockMay 8, 2024 | americanbankingnews.comCorvus Pharmaceuticals (NASDAQ:CRVS) Given New $8.00 Price Target at OppenheimerMay 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comQ1 2024 Corvus Pharmaceuticals Inc Earnings CallMay 11, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.May 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 6, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 4, 2024 | americanbankingnews.comCorvus Pharmaceuticals (CRVS) Scheduled to Post Earnings on MondayMay 2, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024May 2, 2024 | globenewswire.comCorvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingMay 1, 2024 | americanbankingnews.comCorvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below 50-Day Moving Average of $1.83April 24, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (CRVS)April 17, 2024 | finance.yahoo.comHere's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 WeeksApril 9, 2024 | globenewswire.comCorvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisMarch 21, 2024 | seekingalpha.comCorvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comQ4 2023 Corvus Pharmaceuticals Inc Earnings CallMarch 19, 2024 | stockhouse.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 16, 2024 | finance.yahoo.comCRVS Apr 2024 4.000 putMarch 13, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024March 9, 2024 | finance.yahoo.comWe Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth CarefullySee More Headlines Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today5/11/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRVS CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$6.88 High Stock Price Target$12.00 Low Stock Price Target$3.50 Potential Upside/Downside+230.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.96% Return on Assets-50.83% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio4.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book3.06Miscellaneous Outstanding Shares49,040,000Free Float33,690,000Market Cap$102.00 million OptionableOptionable Beta1.05 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Richard A. Miller M.D. (Age 73)Co-Founder, President, CEO & Chairman of the Board Comp: $306kDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Director Comp: $47kMr. Leiv Lea (Age 70)Chief Financial Officer Comp: $388.73kDr. William Benton Jones Ph.D. (Age 58)Senior Vice President of Pharmaceutical Development Comp: $346.42kDr. James T. Rosenbaum M.D.Senior Vice President of ResearchMr. Jeffrey S. ArcaraChief Business OfficerMore ExecutivesKey CompetitorsJaguar HealthNASDAQ:JAGXHookipa PharmaNASDAQ:HOOKConnect BiopharmaNASDAQ:CNTBLifeVantageNASDAQ:LFVNTempest TherapeuticsNASDAQ:TPSTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 142,724 shares on 5/10/2024Ownership: 3.045%Towerview LLCSold 54,373 shares on 5/7/2024Ownership: 0.780%Richard A Md MillerBought 577,634 shares on 5/6/2024Total: $999,306.82 ($1.73/share)William Benton JonesBought 20,000 shares on 5/6/2024Total: $34,600.00 ($1.73/share)Linda GraisBought 10,000 shares on 5/15/2023Total: $24,500.00 ($2.45/share)View All Insider TransactionsView All Institutional Transactions CRVS Stock Analysis - Frequently Asked Questions Should I buy or sell Corvus Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRVS shares. View CRVS analyst ratings or view top-rated stocks. What is Corvus Pharmaceuticals' stock price target for 2024? 3 brokerages have issued 1 year price targets for Corvus Pharmaceuticals' shares. Their CRVS share price targets range from $3.50 to $12.00. On average, they expect the company's share price to reach $6.88 in the next twelve months. This suggests a possible upside of 230.5% from the stock's current price. View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts. How have CRVS shares performed in 2024? Corvus Pharmaceuticals' stock was trading at $1.76 on January 1st, 2024. Since then, CRVS shares have increased by 18.2% and is now trading at $2.08. View the best growth stocks for 2024 here. When is Corvus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CRVS earnings forecast. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO? 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO). When did Corvus Pharmaceuticals IPO? Corvus Pharmaceuticals (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.05%), Towerview LLC (0.78%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Leiv Lea, Linda Grais, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRVS) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
